Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [41] Delayed Chronic Kidney Disease (CKD) Diagnosis in Type 2 Diabetes (T2D)
    Harindhanavudhi, Tasma
    Freese, Rebecca L.
    Caramori, Luiza
    DIABETES, 2021, 70
  • [42] Diagnosis and management of chronic kidney disease
    Graves, John W.
    MAYO CLINIC PROCEEDINGS, 2008, 83 (09) : 1064 - 1069
  • [43] Making treatment guideline recommendations in chronic kidney disease and type 2 diabetes more accessible to primary care providers in the United States
    Wright, Eugene E.
    Nicholas, Susanne B.
    POSTGRADUATE MEDICINE, 2024, 136 (04) : 347 - 357
  • [44] Chronic kidney disease and peripheral artery disease in type 2 diabetes
    Chu, Chih-Hsun
    Sun, Chun-Chin
    Chuang, Wan-Chi
    Chang, Wei-Cheng
    Tsai, Yu-Hsuan
    Kao, Wang-Jung
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S68 - S69
  • [45] Screening and Diagnosis of Type 2 Diabetes in Sickle Cell Disease
    Carrithers, Bria
    Klein, Rachel
    Ovalle, Fernando
    Kanter, Julie
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2025, 37 (05) : 919 - 922
  • [46] AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D)
    Chu, Lisa
    Bhogal, Sanjit K.
    Lin, Peter
    Steele, Andrew
    Fuller, Mark
    Ciaccia, Antonio
    Abitbol, Alexander
    CANADIAN JOURNAL OF DIABETES, 2022, 46 (05) : 464 - 472
  • [47] The Canadian recommendations on screening for type 2 diabetes
    Wald, Nicholas J.
    Haddow, James E.
    JOURNAL OF MEDICAL SCREENING, 2012, 19 (04) : 163 - 163
  • [48] Recommendations on screening for type 2 diabetes in adults
    Pottie, Kevin
    Jaramillo, Alejandra
    Lewin, Gabriela
    Dickinson, Jim
    Bell, Neil
    Brauer, Paula
    Dunfield, Lesley
    Joffres, Michel
    Singh, Harminder
    Tonelli, Marcello
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2012, 184 (15) : 1687 - 1696
  • [49] Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
    Moura-Neto, Jose A.
    Ronco, Claudio
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11):
  • [50] Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
    Mann, Johannes F. E.
    Fonseca, Vivian A.
    Poulter, Neil R.
    Raz, Itamar
    Idorn, Thomas
    Rasmussen, Soren
    von Scholten, Bernt Johan
    Mosenzon, Ofri
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (04): : 465 - 473